case report, we described anesthetic management of a pregnant patient with ruptured AVM posted for CS.
CASE REPORT
A 32-year-old primipara with 5′2″ height and 60 kg weight presented to the emergency department at 38 weeks of gestation with sudden onset of headache along with severe vomiting and left hemiparesis since morning. It was not associated with loss of consciousness or seizures. Medical history was significant for such migrainous headaches on and off in the parietal area since the 7 th month of pregnancy. Her prenatal course was uneventful except for a few episodes of vomiting throughout pregnancy.
On examination, the patient was conscious and cooperative with blood pressure (BP) of 170/110 mmHg, pulse rate (PR) of 120/min, and oxygen saturation of 99%. On neurological examination, power in the left upper and lower limb was Grade II. Neurosurgery consultation was sought and the patient was advised for magnetic resonance imaging of the brain with cerebral angiogram and fundus examination. Magnetic resonance angiogram revealed a bunch of dilated and tortuous vessels suggestive of AVM in the right parietal lobe with hemorrhagic component [ Figure 1 ]. Venous drainage appeared to be in superior sagittal sinus through prominent cortical veins. Fundus examination revealed bilateral papilledema. Obstetrician planned to terminate the pregnancy by CS after medical stabilization of the patient. Measures to reduce intracranial pressure (ICP) with intravenous (IV) mannitol (60 g followed by 20 g every 8 h) and IV steroid (dexamethasone 8 mg every 6 h) and seizure prophylaxis with IV phenytoin (900 mg over 30 min followed by 100 mg every 8 h) were started. Definitive treatment of AVM was postponed till the termination of pregnancy.
All the routine investigations were performed and reports were unremarkable. The sample was also sent for blood grouping and crossmatching. Aspiration prophylaxis with IV ranitidine (50 mg) and sodium citrate suspension (30 ml) was given.
After medical stabilization, the patient was taken to the operation room (OR). General anesthesia (GA) was planned considering raised ICP. In OR, continuous monitoring such as electrocardiography, pulse oximetry, and capnography was applied and baseline vitals were recorded. Arterial line was secured under local anesthesia (LA) in the right radial artery with 20 gauge IV cannula for invasive BP monitoring. The patient was premedicated with IV fentanyl 60 mcg, magnesium sulfate 2 g, and midazolam 1 mg, 15 min before induction. Preoxygenation with 100% oxygen (O 2 ) was done for 3 min. Induction was done with IV propofol 120 mg with continuous cricoid pressure. Muscle relaxation was provided with IV rocuronium 60 mg. Hemodynamic stress response to laryngoscopy was prevented using IV nitroglycerine (NTG) (30 mcg/min) and IV lignocaine (60 mg) before intubation. The trachea was intubated with a 7.0 mm inner diameter cuffed endotracheal tube in the first attempt without any difficulty. A left lateral tilt (to decrease pressure on the inferior vena cava) and 15° reverse Trendelenburg tilt (to decrease ICP) was applied to the operation table. The patient was mechanically ventilated with a tidal volume of 8 ml/kg and a respiratory rate sufficient to maintain end-tidal CO 2 around 30 mmHg. Anesthesia was maintained with nitrous oxide and O 2 (60:40) mixture and continuous infusion of propofol (100 mcg/min). After delivery of the baby, IV oxytocin 5 unit bolus and 5 units in 500 ml 0.9% NaCl infusion were started. IV fentanyl 60 mcg was repeated following the delivery. Apgar scores were 8 and 10 at the 1 st and the 5 th min, respectively. NTG infusion continued and titrated accordingly to maintain mean arterial pressure (MAP) around 70 mm Hg so as to maintain adequate ICP and uteroplacental perfusion.
At closure, the LA agent was infiltrated along the suture line for postoperative analgesia. Following completion of the surgical procedure, muscle relaxation was reversed with IV neostigmine 2.5 mg and IV glycopyrrolate 0.5 mg. The trachea was extubated when the patient responded to verbal stimulation. There was neither any significant hemodynamic change nor any further neurological deterioration in the OR and postanesthesia care unit. Postoperative analgesia was maintained with 1 g of IV paracetamol every 6 h and IV tramadol 50 mg sos. Patient was discharged on day 6 postpartum, clinically stable and referred for the interventional neuroradiology consultation for definitive management of AVM.
DISCUSSION
AVMs are defects of the circulatory system comprising snarled tangles of arteries and veins. The absence of capillaries creates a shortcut for blood to pass directly from arteries to veins. Although their cause is not known, they are generally believed to arise during embryonic development or soon after birth. [10] Brain AVMs are of special concern because of the damage they cause when they bleed. AVM damages the brain through three basic mechanisms: By reducing the amount of O 2 reaching neurological tissues, by causing bleeding (hemorrhage) into surrounding tissues, and by compressing or displacing parts of the brain. [10] Previously, it was thought that pregnancy increases the risk of hemorrhage from an AVM due to the increased blood circulation that occurs during pregnancy. Robinson et al. [11] evaluated 24 cases of AVM and concluded that a woman who has had AVM would have 87% chances of developing ICH during pregnancy. While recently Horton et al. [9] studied 451 women with AVM and concluded that pregnancy does not increase the risk of bleeding of an AVM, estimating it at 3.5% in pregnant versus 3.1% in nonpregnant female. Commonly, hemorrhage due to AVM in pregnant women occurs at 15-20 th weeks, but it may occur at any stage including during labor or in the puerperium. [12] Although not all AVMs bleed during pregnancy, it is recommended to delay pregnancy until after the AVM has been completely treated. [13] Although the best strategy for management of symptomatic AVM during pregnancy is not yet defined, the risk-benefit analysis seems not to support the elective treatment of AVM during pregnancy. [2] It is believed that uterine contractions of labor and the Valsalva effect of vaginal delivery are accompanied by dramatic and transient increases in venous pressure, cardiac output, and ICP, so most clinicians advocate delivery by CS.
Osmotic diuresis with mannitol was used for decreasing ICP. Animal and human studies have proposed that mannitol causes fetal hypovolemia and electrolyte imbalance. However, there is no evidence of mannitol 0.5-1 g/kg having any significant effect on fetal fluid balance. [14] Dexamethasone was used to decrease cerebral edema. Its acute use may be safe for fetus, but chronic use may result in fetal adrenal suppression and fetal hypoadrenalism, particularly during the third trimester. [15] There are very few published reports of anesthetic management for pregnant women with symptomatic AVM. [1, 7, [16] [17] [18] [19] Successful anesthetic management requires close monitoring to address both the varying maternal and fetal needs. The fundamental aims are to maintain oxygenation and stable systemic, cerebral, and placental hemodynamics and to avoid increase in ICP. [20] The regional anesthetic technique could be preferred because it avoids the hemodynamic stress associated with laryngoscopy, intubation, and extubation during GA. [16, 17] In our case, because of the raised ICP, we preferred GA and hemodynamic stress was prevented using NTG, fentanyl, lidocaine, and magnesium sulfate. During the maintenance of anesthesia, invasive BP monitoring was used to prevent exaggerated hemodynamic perturbation. We maintained both the cerebral perfusion and the uteroplacental perfusion by keeping MAP within normal limits (65-90 mmHg). Oxytocin has been used in patients with intracranial tumors without any adverse effect. [15] On the other hand, ergotamine has been associated with hypertensive responses, which may increase ICP more.
CONCLUSION
In a pregnant patient with symptomatic AVM, GA can be used satisfactorily for cesarean delivery keeping in mind hemodynamic stability to maintain adequate cerebral and uteroplacental perfusion and to avoid further increase in ICP. Measures to reduce ICP should be started during preoperative period and should be continued during intra-and post-operative periods.
